Home
Calimmune, Inc.

Calimmune, Inc. Market Share Analysis for May 2026

Industry: N/A

Domaincalimmune.com

Year Founded2006

Employees51 - 200

Annual Revenue$5M - $10M

Calimmune, Inc.

Calimmune, Inc. (including company regionals)

calimmune.com

See more website traffic and engagement information

Calimmune, Inc. Revenue up to May 2026 is 5M - 10M

revenue generated by Calimmune, Inc. top domains

Calimmune, Inc. top domains revenue over 3 years

Revenue for Calimmune, Inc. top domains

calimmune.com5M - 10M

See more with Sales Intelligence

Total visits to Calimmune, Inc.'s top domains

Understand Calimmune, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Calimmune, Inc.'s top domains

Analyze Calimmune, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Calimmune, Inc.'s top domains

See how Calimmune, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Calimmune, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Calimmune, Inc.

These are the website technologies, by industry, used by Calimmune, Inc. top domains

Content Management System (3)

WordPress

Audio Video Media (2)

Vimeo

Conversion & Analytics (1)

Google Analytics

Mobile (1)

Meta Viewport

More Technologies

3

See all

News & Signals from Calimmune, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCSL Behring AG acquired Calimmune for $91M on Aug 28th '17.CSL Behring, the US subsidiary of Australia-based CSL has agreed to acquire Calimmune, an American biotechnology company focused on developing ex vivo hematopoietic stem cell (HSC) gene therapy.

NewsCalimmune is developing stem-cell gene therapy on Jan 1st '06.Calimmune, co-founded by UA biology grad and entrepreneur Louis Breton in 2006, is developing stem-cell gene therapy to strengthen patients’ own immune systems.

NewsCSL Limited acquired Calimmune for $91M on Aug 1st '17.Blood product and vaccine manufacturer CSL Limited (ASX: CSL) this morning announced that it has agreed to acquire US biotechnology Calimmune for the sum of $91 million.